{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Scully KJ"],"funding":["National Institute of Diabetes and Digestive and Kidney Diseases","NIDDK NIH HHS","National Institutes of Health","Cystic Fibrosis Foundation Clinical Research Award"],"pagination":["e1444-e1454"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8947309"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["107(4)"],"pubmed_abstract":["<h4>Context</h4>The clinical utility and implications of continuous glucose monitoring (CGM) in cystic fibrosis (CF) are unclear.<h4>Objective</h4>We examined the correlation between CGM measures and clinical outcomes in adults with CF, investigated the relationship between hemoglobin A1c (HbA1c) and CGM-derived average glucose (AG), and explored CGM measures that distinguish cystic fibrosis-related diabetes (CFRD) from normal and abnormal glucose tolerance.<h4>Methods</h4>This prospective observational study included 77 adults with CF who had CGM and HbA1c measured at 2 to 3 time points 3 months apart.<h4>Results</h4>Thirty-one of the 77 participants met American Diabetes Association-recommended diagnostic criteria for CFRD by oral glucose tolerance testing and/or HbA1c. In all participan"],"journal":["The Journal of clinical endocrinology and metabolism"],"pubmed_title":["Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis."],"pmcid":["PMC8947309"],"funding_grant_id":["PUTMAN16A0","T32 DK007699","5T32DK007699"],"pubmed_authors":["Sherwood JS","Wexler DJ","Ruazol M","Sawicki GS","Uluer A","Marchetti P","Larkin M","Zheng H","Putman MS","Martin K","Yonker LM","Sicilian L","Neuringer I","Scully KJ"],"additional_accession":[]},"is_claimable":false,"name":"Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis.","description":"<h4>Context</h4>The clinical utility and implications of continuous glucose monitoring (CGM) in cystic fibrosis (CF) are unclear.<h4>Objective</h4>We examined the correlation between CGM measures and clinical outcomes in adults with CF, investigated the relationship between hemoglobin A1c (HbA1c) and CGM-derived average glucose (AG), and explored CGM measures that distinguish cystic fibrosis-related diabetes (CFRD) from normal and abnormal glucose tolerance.<h4>Methods</h4>This prospective observational study included 77 adults with CF who had CGM and HbA1c measured at 2 to 3 time points 3 months apart.<h4>Results</h4>Thirty-one of the 77 participants met American Diabetes Association-recommended diagnostic criteria for CFRD by oral glucose tolerance testing and/or HbA1c. In all participan","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-19T22:47:01.61Z","creation":"2025-04-19T22:47:01.61Z"},"accession":"S-EPMC8947309","cross_references":{"pubmed":["34850006"],"doi":["10.1210/clinem/dgab857"]}}